CEO and CFO to depart GlycoMimetics by March 31; will consult through merger close

CRESCENT BIOPHARMA, INC.

CEO Harout Semerjian and CFO Brian Hahn notified board of intent to resign by March 31, 2025.
Both expected to enter consulting agreements through expected close of merger with Crescent Biopharma.
Departures coincide with pending merger; no replacements named yet.
Notice date: January 29, 2025.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Hahn

Chief Financial Officer

CBIO · CRESCENT BIOPHARMA, INC.

Effective: 2025-03-31
Filed: January 31, 2025, 6:59 PM ET

Mr. Brian Hahn, the Company’s Chief Financial Officer, notified the Company’s board of directors of his intent to cease his respective employment with the Company no later than March 31, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Brian Hahn resigned as Chief Financial Officer at CRESCENT BIOPHARMA, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Mr. Brian Hahn, the Company’s Chief Financial Officer, notified the Company’s board of directors of his intent to cease his respective employment with the Company no later than March 31, 2025.

View on SEC.gov

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-25-000576

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.